0001209191-20-057338.txt : 20201106
0001209191-20-057338.hdr.sgml : 20201106
20201106175720
ACCESSION NUMBER: 0001209191-20-057338
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201104
FILED AS OF DATE: 20201106
DATE AS OF CHANGE: 20201106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Prout Samantha
CENTRAL INDEX KEY: 0001743122
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33497
FILM NUMBER: 201295504
MAIL ADDRESS:
STREET 1: C/O AMICUS THERAPEUTICS, INC.
STREET 2: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
FORMER NAME:
FORMER CONFORMED NAME: Prout Samantha Whiteman
DATE OF NAME CHANGE: 20180607
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001178879
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200422823
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
BUSINESS PHONE: (609) 662-2000
MAIL ADDRESS:
STREET 1: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
FORMER COMPANY:
FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC
DATE OF NAME CHANGE: 20020729
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-04
0
0001178879
AMICUS THERAPEUTICS, INC.
FOLD
0001743122
Prout Samantha
C/O AMICUS THERAPEUTICS, INC.
1 CEDAR BROOK DRIVE
CRANBURY
NJ
08512
0
1
0
0
Principal Accounting Officer
Common Stock
2020-11-04
4
M
0
5337
14.88
A
22472
D
Common Stock
2020-11-04
4
M
0
594
10.04
A
23066
D
Common Stock
2020-11-04
4
S
0
5931
20.00
D
17135
D
Stock Options (right to buy)
14.88
2020-11-04
4
M
0
5337
0.00
D
2028-03-26
Common Stock
5337
2940
D
Stock Options (right to buy)
10.04
2020-11-04
4
M
0
594
0.00
D
2029-01-02
Common Stock
594
5148
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
As of November 4, 2020, 5,337 options were fully vested and exercisable and 2,940 remained unvested from this grant.
As of November 4, 2020, 594 options were fully vested and exercisable and 5,148 remained unvested from this grant.
/s/ Christian Formica, Attorney-in-Fact
2020-11-06